FCF Biotech Venture Capital Monitor – USA 06/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 06/2023”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of  June 2023, we identify the following current VC trends in the US-Biotech sector:

  • In 2023, overall Biotech funding in the USA has reached USD 9,562m
  • Compared to June 2022 the financing volume decreased twofold (20,106m vs. 9,562m)
  • Oncology dominates as the top indication
  • Upstream Bio has the highest transaction Volume of USD 200m in June, followed by Alkeus Pharmaceuticals USD 150m and Bitterroot Bio USD 145m
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by Alexandria Venture Investments (USA) and Google Ventures (USA)
  • The top 5 deals exceed USD 190m each, largest transaction amounted to USD 401m in ElevateBio

To access the full report, please click here.

By Mathias Klozenbücher, Johannes Link and Marcel-Louis Christou.